Pediatric Nephrology

, Volume 33, Issue 2, pp 325–333 | Cite as

Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease

  • Sahar Fathallah-Shaykh
  • Dorota Drozdz
  • Joseph Flynn
  • Randall Jenkins
  • Katherine Wesseling-Perry
  • Sarah J. Swartz
  • Craig Wong
  • Beverly Accomando
  • Gerald F. Cox
  • Bradley A. Warady
Original Article



Treatment for hyperphosphatemia in chronic kidney disease (CKD) involves dietary control of phosphorus intake, dialysis, and treatment with oral phosphate binders, none of which were approved by the Federal Food and Drug Administration in pediatric patients at the time of this study.


This was a phase 2, multicenter study (NCT01574326) with a 2-week, randomized, placebo-controlled, fixed-dose period (FDP) followed by a 6-month, single-arm, open-label, dose-titration period (DTP), with the aim to evaluate the safety and efficacy of sevelamer carbonate (SC) in hyperphosphatemic pediatric patients with CKD. Following a 2–4 week screening phase, pediatric patients with a serum phosphorus level higher than age-appropriate levels were randomized to receive either SC or placebo as powder/tablets in 0.4–1.6 g doses, based on body surface area. The primary efficacy outcome was the change in serum phosphorus from baseline to end of the FDP in the SC versus placebo arms (analysis of covariance). The secondary outcome was mean change in serum phosphorus from baseline to end of DTP by treatment group and overall. Treatment-emergent/serious adverse events (AEs) were recorded.


Of 101 enrolled patients (29 centers), 66 completed the study. The majority of patients were adolescents (74%; mean age 14.1 years) and on dialysis (77%). Renal transplant was the main reason for discontinuation. SC significantly reduced serum phosphorus from baseline levels (7.16 mg/dL) during the FDP compared to placebo (least square mean difference − 0.90 mg/dL, p = 0.001) and during the DTP (− 1.18 mg/dL, p < 0.0001). The safety and tolerability of SC and placebo were similar during the FDP, with patients in both groups reporting mild/moderate gastrointestinal AEs during the DTP.


Sevelamer carbonate significantly lowered serum phosphorus levels in hyperphosphatemic children with CKD, with no serious safety concerns identified.


Chronic kidney disease Hyperphosphatemia Pediatric patients Sevelamer carbonate Phosphate binder 



The authors acknowledge Mark Benfield MD, Pediatric Nephrology of Alabama, Phenix City, AL, for his contributions to the study, and Gill Sperrin, CBiol, MRSB, CMPP, and Priyanka Narang, PhD, of Envision Scientific Solutions, for editorial support in the preparation of this publication, sponsored by Sanofi. The authors were responsible for all content and editorial decisions and received no honoraria related to the development of this publication. This study was funded by Sanofi.

Data availability

Interested researchers may request access to anonymized patient-level data and clinical study documents related to this publication at

Compliance with ethical standards

Informed consent

The first patient signed informed consent on 11 May 2012, and the last patient completed the last visit on 16 June 2015.

Ethical approval

The trial was conducted in accordance with the International Conference on Harmonization/Good Clinical Practice guidelines. The protocol also complied with the laws and regulations of the countries where the study was conducted. The study received approval from local Institutional Review Boards/Independent Ethics Committees.

Conflict of interest

This study was funded by Sanofi. JF, SFS, DD and SJS have no conflict to declare. RJ receives research funding from Arbor Pharmaceuticals and is a scientific advisor for The Mike Program, Portland, OR. KWP receives research funding from Sanofi and Genentech. CW receives honoraria from UpToDate®. BA is currently employed by Sanofi. GFC was employed by Sanofi at the time of the study. He is currently employed by Editas Medicine. BAW is a consultant for Amgen, Baxter, Keryx, and Rockwell; receives research funding from Baxter and NIH; receives honoraria from Amgen, Rockwell, and UpToDate®, and is a board member of the North American Pediatric Renal Trials and Collaborative Studies, and the National Kidney Foundation.

Supplementary material

467_2017_3787_MOESM1_ESM.docx (12 kb)
Table S1 (DOCX 11 kb)
467_2017_3787_Fig4_ESM.gif (66 kb)
Fig. S1

Subgroup analyses on changes in serum phosphorus levels from baseline during the fixed dose period—full Analysis Set (GIF 66.3 kb)

467_2017_3787_MOESM2_ESM.eps (1.5 mb)
High Resolution (EPS 1512 kb)


  1. 1.
    Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607–617Google Scholar
  2. 2.
    Wesseling K, Bakkaloglu S, Salusky I (2008) Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol 23:195–207CrossRefPubMedGoogle Scholar
  3. 3.
    Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218CrossRefPubMedGoogle Scholar
  4. 4.
    Pieper AK, Haffner D, Hoppe B, Dittrich K, Offner G, Bonzel KE, John U, Frund S, Klaus G, Stubinger A, Duker G, Querfeld U (2006) A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis 47:625–635CrossRefPubMedGoogle Scholar
  5. 5.
    Klaus G, Watson A, Edefonti A, Fischbach M, Ronnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schroder C, Zurowska A, Ekim M (2006) Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21:151–159CrossRefPubMedGoogle Scholar
  6. 6.
    Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM (2008) Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 118:1748–1757CrossRefPubMedGoogle Scholar
  7. 7.
    Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483CrossRefPubMedGoogle Scholar
  8. 8.
    Hutchison AJ (2009) Oral phosphate binders. Kidney Int 75:906–914CrossRefPubMedGoogle Scholar
  9. 9.
    Gonzalez E, Schomberg J, Amin N, Salusky IB, Zaritsky J (2010) Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr Nephrol 25:373–375CrossRefPubMedGoogle Scholar
  10. 10.
    Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ (2007) A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 68:386–391CrossRefPubMedGoogle Scholar
  11. 11.
    Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, Plone M, Pritchard N (2009) A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 24:3794–3799CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Pai AB, Shepler BM (2009) Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 29:554–561CrossRefPubMedGoogle Scholar
  13. 13.
    Coppolino G, Lucisano S, Rivoli L, Fuiano G, Villari A, Villari I, Leonello G, Lacquaniti A, Santoro D, Buemi M (2015) Sevalamer hydrochloride, sevelamer carbonate and lanthanum carbonate: in vitro and in vivo effects on gastric environment. Ther Apher Dial 19:471–476CrossRefPubMedGoogle Scholar
  14. 14.
    Borzecki AM, Lee A, Wang SW, Brenner L, Kazis LE (2007) Survival in end stage renal disease: calcium carbonate vs. sevelamer. J Clin Pharm Ther 32:617–624CrossRefPubMedGoogle Scholar
  15. 15.
    Filiopoulos V, Koutis I, Trompouki S, Hadjiyannakos D, Lazarou D, Vlassopoulos D (2011) Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. Ther Apher Dial 15:20–27CrossRefPubMedGoogle Scholar
  16. 16.
    Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH (2008) Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19:405–412CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ (2004) Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J 25:785–791PubMedGoogle Scholar
  18. 18.
    Querfeld U (2005) The therapeutic potential of novel phosphate binders. Pediatr Nephrol 20:389–392CrossRefPubMedGoogle Scholar
  19. 19.
    National Kidney Foundation (2009) KDOQI clinical practice guideline for nutrition in children with CKD. Am J Kidney Dis 53:S67CrossRefGoogle Scholar
  20. 20.
    Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S (2010) A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Am J Kidney Dis 55:307–315CrossRefPubMedGoogle Scholar
  21. 21.
    Van Breukelen GJP (2006) ANCOVA versus change from baseline: more power in randomized studies, more bias in nonrandomized studies [corrected]. J Clin Epidemiol 59:920–925CrossRefPubMedGoogle Scholar
  22. 22.
    Moustafa M, Lehrner L, Al-Saghir F, Smith M, Goyal S, Dillon M, Hunter J, Holmes-Farley R (2014) A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis. Int J Nephrol Renov Dis 7:141–152Google Scholar
  23. 23.
    Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK (2001) Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131–2138PubMedGoogle Scholar
  24. 24.
    Kestenbaum B, Belozeroff V (2007) Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Investig 37:607–622CrossRefGoogle Scholar
  25. 25.
    Goodman WG (2004) Importance of hyperphosphataemia in the cardio-renal axis. Nephrol Dial Transplant 19[Suppl 1]:i4–i8CrossRefPubMedGoogle Scholar
  26. 26.
    Shroff R (2011) Dysregulated mineral metabolism in children with chronic kidney disease. Curr Opin Nephrol Hypertens 20:233–240CrossRefPubMedGoogle Scholar
  27. 27.
    Shroff RC, Donald AE, Hiorns MP, Watson A, Feather S, Milford D, Ellins EA, Storry C, Ridout D, Deanfield J, Rees L (2007) Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 18:2996–3003CrossRefPubMedGoogle Scholar
  28. 28.
    Querfeld U (2004) The clinical significance of vascular calcification in young patients with end-stage renal disease. Pediatr Nephrol 19:478–484CrossRefPubMedGoogle Scholar
  29. 29.
    Rees L, Azocar M, Borzych D, Watson AR, Buscher A, Edefonti A, Bilge I, Askenazi D, Leozappa G, Gonzales C, van Hoeck K, Secker D, Zurowska A, Ronnholm K, Bouts AH, Stewart H, Ariceta G, Ranchin B, Warady BA, Schaefer F (2011) Growth in very young children undergoing chronic peritoneal dialysis. J Am Soc Nephrol 22:2303–2312CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Fabio M (2013) Hyperphosphataemia: treatment options. Drugs:1–16Google Scholar
  31. 31.
    Rees L, Shroff R (2015) The demise of calcium-based phosphate binders-is this appropriate for children? Pediatr Nephrol 30:2061–2071CrossRefPubMedGoogle Scholar
  32. 32.
    Sekercioglu N, Thabane L, Diaz Martinez JP, Nesrallah G, Longo CJ, Busse JW, Akhtar-Danesh N, Agarwal A, Al-Khalifah R, Iorio A, Guyatt GH (2016) Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis. PLoS One 11:e0156891CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Oka Y, Miyazaki M, Takatsu S, Oohara T, Toda K, Uno F, Matsuda H (2008) A review article: sevelamer hydrochloride and metabolic acidosis in dialysis patients. Cardiovasc Hematol Disord Drug Targets 8:283–286CrossRefPubMedGoogle Scholar
  34. 34.
    Green J, Maor G (2000) Effect of metabolic acidosis on the growth hormone/IGF-I endocrine axis in skeletal growth centers. Kidney Int 57:2258–2267CrossRefPubMedGoogle Scholar
  35. 35.
    Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, Bellasi A (2013) Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62:771–778CrossRefPubMedGoogle Scholar
  36. 36.
    Barna MM, Kapoian T, O'Mara NB (2010) Sevelamer carbonate. Ann Pharmacother 44:127–134CrossRefPubMedGoogle Scholar

Copyright information

© IPNA 2017

Authors and Affiliations

  • Sahar Fathallah-Shaykh
    • 1
  • Dorota Drozdz
    • 2
  • Joseph Flynn
    • 3
  • Randall Jenkins
    • 4
  • Katherine Wesseling-Perry
    • 5
  • Sarah J. Swartz
    • 6
  • Craig Wong
    • 7
  • Beverly Accomando
    • 8
  • Gerald F. Cox
    • 8
    • 9
  • Bradley A. Warady
    • 10
  1. 1.University of Alabama at BirminghamBirminghamUSA
  2. 2.Jagiellonian University Medical CollegeKrakowPoland
  3. 3.Seattle Children’s HospitalSeattleUSA
  4. 4.Oregon Health and Science UniversityPortlandUSA
  5. 5.University of CaliforniaLos AngelesUSA
  6. 6.Texas Children’s HospitalBaylor College of MedicineHoustonUSA
  7. 7.University of New Mexico Health Sciences CenterAlbuquerqueUSA
  8. 8.SanofiCambridgeUSA
  9. 9.Editas MedicineCambridgeUSA
  10. 10.Children’s Mercy Kansas CityKansas CityUSA

Personalised recommendations